Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived

European Journal of Haematology

Volumn 83, Issue 5, 2009, Pages 449-454

  Corso, Alessandro ^a   Varettoni, Marzia ^a   Mangiacavalli, Silvia ^a   Zappasodi, Patrizia ^a   Pica, Gian Matteo ^a   Algarotti, Alessandra ^a   Pascutto, Cristiana ^a   Lazzarino, Mario ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Bortezomib; Dexamethasone; Neuropathy; Relapsed refractory myeloma

Indexed keywords

ANALGESIC AGENT; BORTEZOMIB; DEXAMETHASONE; GABAPENTIN; IMMUNOGLOBULIN LIGHT CHAIN; M PROTEIN; PREGABALIN; THALIDOMIDE;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HERPES ZOSTER; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHIC PAIN; PAIN; PERIPHERAL NEUROPATHY; PLASMACYTOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RASH; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR VOLUME; VASCULITIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 70349971700     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01295.x     Document Type: Article

References (19)

1. Gertz MA, Kalish LA, Kyle RA, Hahn RG, Tormey DC, Oken MM. Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed MM: an Eastern Cooperative Oncology Group study. Am J Clin Oncol 1995 18 : 475 480.
2. Bladé J, Esteve J. Treatment approaches for relapsing and refractory MM. Acta Oncol 2000 39 : 843 847.
3. Kumar SK, Therneau TM, Gertz MA, et al. Clinical course of patients with relapsed MM. Mayo Clin Proc 2004 79 : 867 874.
4. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of Bortezomib in relapsed, refractory myeloma. N Engl J Med 2003 348 : 2609 2617.
5. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of Bortezomib in relapsed or refractory myeloma. Br J Haematol 2004 127 : 165 172.
6. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005 352 : 2487 2498.
7. Richardson P, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results from the APEX trial. Blood 2007 110 : 3557 3560.
8. Durie BGM, Harousseau JL, Miguel JS, et al. International uniform response criteria for MM. Leukemia 2006 20 : 1467 1473.
9. Millennium Pharmaceuticals, Inc. VelcadeTM (Bortezomib) for Injection. Prescribing Information. Cambridge, MA : Millennium Pharmaceuticals, Inc., 2004.
10. Mikhael J, Belch A, Prince M, Nambo Lucio M, Maiolino A, Corso A, Petrucci MT, Musto P, Komarnicki M, Stewart AK. Safety and efficacy results from an international phase 3B study for expanded access to Bortezomib in patients with relapsed and/or refractory MM. Br J Haematol 2008 144 : 169 175.
11. Jagannath S, Richardson PG, Barbogie B, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory MM with less than optimal response to Bortezomib alone. Haematologica 2006 91 : 929 934.
12. Rosiñol L, Cibeira MT, Uriburu C, Yantorno S, Salamero O, Bladè J, Montserrat E. Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol, 2006 76 : 405 408.
13. Richardson PG, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Chauhan D, Munsi N, Anderson K. The treatment of relapsed and refractory multiple myeloma. Hematology Am Soc Hematol Educ Program 2007 317 323.
14. Bladè J, Rosiñol L. Advances in therapy of multiple myeloma. Curr Opin Oncol 2008 20 : 697 704.
15. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin DH, Rajkumar SV, Srkalovic G, Alsina M, Anderson KC. Extended follow-up of a phase II trial in relapsed refractory MM. Final time-to-event results from the SUMMIT trial. Cancer 2006 106 : 1316 1319.
16. Richardson PG, Barlogie B, Berenson J, et al. Clinical factors predictive of outcome with Bortezomib in patients with relapsed, refractory MM. Blood 2005 106 : 2977 2981. (Pubitemid 41565888)
17. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of PN during treatment of advanced MM with Bortezomib. J Clin Oncol, 2006 24 : 3113 3120.
18. Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-centre experience and review of literature. Cancer 2007 110 : 1042 1049.
19. Mateos MV, Hernández J, Hernández MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with MM: results of a multicenter phase 1/2 study. Blood 2006 108 : 2165 2172.